Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Choosing between SP 500 and multi-asset strategies depends on goals and risk comfort. This intro contrasts outcomes to guide retirement design.
26,826 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Tesla unveils Terafab, a new in-house semiconductor fabrication unit focused on robotics and AI chips. Early signals ...
A CertiK report reveals 34 verified crypto wrench attacks globally, up 41% from last year. Victims’ families are incr...
Meta Platforms is down about 11% in a month as Alphabet climbs roughly 16%, driven by AI-driven revenue signals. The ...
Meta Platforms has built immense value on advertising, but a subscription-based approach could balance revenue stream...
CrowdStrike is approaching a stock split, but smart investors look beyond the headline. Here are three solid reasons ...
Nvidia sits at the center of a rapid AI infrastructure buildout. Here’s how the stock could move by 2029, based on gr...
A high-stakes NBA scenario puts investor attention on payroll, sponsorships, and market bets. The potential LeBron mo...
Seoul unveiled a sweeping AI infrastructure plan valued at south korea’s $576 billion, a move that investors say coul...
Evercore ISI launches SpaceX coverage with an Outperform rating and a $230 target, fueling a new wall street spacex b...
AI misinfo is not just a tech issue—it's a real-world risk that can touch markets, portfolios, and lives. This articl...
A private AI startup is offering a sub-$1 pre-IPO round open to retail investors, pricing shares at $0.66 and promisi...